Numerous articles, including two case-control studies, have been published documenting a causal association between the use of oral contraceptives and benign liver tumours, variously described as adenomas or focal nodular hyperplasia (Baum et al., 1973; Edmondson et al., 1976; Rooks et al., 1979) Cancer, 1974; Yager & Yager, 1980; Wanless & Medline, 1982) , and at least 10 case reports of hepatocellular carcinoma arising in women taking oral contraceptives have been published (Meyer et al., 1974; Thalissinos et al., 1974; Davis et al., 1975; Glasberg & Rosenbaum, 1976; Mays et al., 1976; O'Sullivan & Rosswick, 1976; Pryor et al., 1977; Trias et al., 1978; Tesluk & Lawrie, 1981) . We now report 11 further cases of malignant liver tumours in young women and document a statistically significant association between these tumours and use of oral contraceptives.
All new cases of liver cancer in U.S.-born women aged 18-39 years occurring during 1975-1980 were obtained from the population-based cancer registry for Los Angeles County (Mack, 1977 (Breslow & Day, 1981) ). This difference was apparent for both single cases and controls, and for married cases and controls. Histopathological material from all of the cases was reviewed by two pathologists (HAE and RLP). Three of the cases (nos. 4, 5 and 10) had typical fibrolamellar carcinomas and one (Case no. 2) a typical microtrabecullar carcinoma. One other (Case no. 7) was a typical well-differentiated hepatocellular carcinoma. In 3 additional cases (Case nos. 3, 6 and 11), the carcinoma was more undifferentiated, but in each case some trabecullar pattern was evident, consistent with the hepatic origin of these neoplasms. In Case no. 11 the hepatocellular carcinoma occurred alongside a benign liver adenoma, typical of the type associated with oral contraceptives (Figure 1 ): the same liver also contained a classic lesion of focal nodular hyperplasia.
The remaining 3 cases (Case nos. 1, 8 and 9) had distinctly unusual liver neoplasms. Case no. 1 had a highly malignant giant cell carcinoma. The neoplasm in Case no. 8 was a sclerosing duct forming carcinoma with features of both cholangiocarcinoma and hepatocellular carcinoma. Case no. 9 was a papillary carcinoma, mostly squamous cell, of the type that could arise in a cyst. This latter tumour, probably the most atypical liver carcinoma of the 11 cases, occurred in a woman who had used oral contraceptives for 168 months. These latter 3 unusual cases all came to autopsy, at which no other primary neoplasms were found.
None of the cases or controls reported a prior history of hepatitis or jaundice. None of the 4 cases tested were HBsAG positive. None of the cases reported job related exposure to any known hepatotoxin such as vinyl chloride. There was no difference in the frequency of alcohol consumption between cases and controls: 7 of the cases consumed no more than an occasional drink.
The clinical, pathological and epidemiological data presented above strongly suggest that longterm oral contraceptive use may cause malignant liver tumours. In one case, the malignant tumour appeared to develop in association with a typical benign liver adenoma-this strongly suggests a common aetiology. No particular oral contraceptive formulation appeared to be responsible for this association. In none of the women was there evidence of exposure to other potential causes of liver cell carcinoma including vinyl chloride, hepatitis B virus, or excessive alcohol intake.
